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Abstract: Individuals who are obese are frequently insulin resistant,
putting them at increased risk of developing type 2 diabetes and its
associated adverse health conditions. The accumulation in adipose
tissue of macrophages in an inﬂammatory state is a hallmark of
obesity-induced insulin resistance. Here, we reveal a role for AMPK
b1 in protecting macrophages from inﬂammation under high lipid
exposure. Genetic deletion of the AMPK b1 subunit in mice (referred
to herein as b1(/) mice) reduced macrophage AMPK activity,
acetyl-CoA carboxylase phosphorylation, and mitochondrial content,
resulting in reduced rates of fatty acid oxidation. b1(/) macro-
phages displayed increased levels of diacylglycerol and markers of
inﬂammation, effects that were reproduced in WT macrophages by
inhibiting fatty acid oxidation and, conversely, prevented by phar-
macological activation of AMPK b1-containing complexes. The effect
of AMPK b1 loss in macrophages was tested in vivo by transplanta-
tion of bone marrow from WT or b1(/) mice into WT recipients.
When challenged with a high-fat diet, mice that received b1(/)
bone marrow displayed enhanced adipose tissue macrophage inﬂam-
mation and liver insulin resistance compared with animals that
received WT bone marrow. Thus, activation of AMPK b1 and increas-
ing fatty acid oxidation in macrophages may represent a new thera-
peutic approach for the treatment of insulin resistance.
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harvard.edu (D. Schuppan).Obesity has long been linked to type 2 diabetes (T2D), but the
involved metabolic dysregulation is incompletely understood.
Galic et al. [1] recently reported that adenosine monophosphate
kinase (AMPK) b1 plays a hitherto unknown role in modulating
obesity-induced insulin resistance. AMPK is a central regulator
of energy balance. Decreased cellular energy status, as reﬂected
by accumulation of AMP, activates AMPK which turns on expres-
sion of catabolic enzymes that permit ATP production and shuts
down energy consuming biosynthetic pathways. Thus, AMPK is
a central regulator of fatty acid, cholesterol, and glucose homeo-
stasis through phosphorylation of metabolism-regulating
enzymes including acetyl-CoA carboxylase (ACC), glycogen syn-
thase (GS), glucose transporter 4 (GLUT4), HMG-CoA reductase,
hormone-sensitive lipase (HSL), and mammalian target of rapa-
mycin (mTOR). AMPK is a heterotrimer of a catalytic a-chain
and regulatory b- and c-chains. There exist several trimers, with
a1b1c1 and a2b1c1 being prominent in the liver, and a2b2c1
and a2b2c3 being found in skeletal and cardiac muscle [2]. More-
over, trimers containing the b1 subunit are prevalent in pancreas
and brown fat, whereas the b2 subunit predominates in brain or
gastric tissue [3].
Although AMPK is a ubiquitous regulator of mitochondrial
activity, little has been known about its role in metabolic regula-
tion of inﬂammatory cells, and studies in non-alcoholic steato-
hepatitis (NASH) have been linked to hepatocyte AMPK [4].
Therefore, investigations into the role of macrophage AMPK are
timely, since these cells have been identiﬁed as central players
in adipose tissue inﬂammation, T2D and NASH [5]. The report
by Galic et al. partly ﬁlls this gap in by showing that macrophage
AMPK regulates fat-induced inﬂammation in both peripheral adi-
pose tissue and fatty liver [1].
The authors ﬁrst conﬁrmed reduced activity of a1 subunit
containing AMPK trimers and increased expression of inﬂamma-
tory cytokines in peritoneal macrophages of leptin deﬁcient ob/ob
mice, which spontaneously develop insulin resistance. In these
mice, downregulated AMPK is likely due to a reduction of adipo-
nectin receptors which are upstream of AMPK [6]. In addition,
they showed that loss of AMPKb1 causes the concomitant reduc-
tion of AMPKa1 in bone marrow-derived mononuclear cells
(BMDM). In the presence of palmitate, these mutant BMDM dis-
played reduced fatty acid oxidation and upregulated expression
of the inﬂammatory cytokines TNFa, IL-6, and IL-1b. Moreover,
the increased ratio of iNOS/Arg1 demonstrated M1-polarization
of macrophages in these BMDM. The relevance of these in vitro
data was then proven in chimeric mice fed a high-fat diet13 vol. 58 j 619–621
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Fig. 1. Scheme depicting the role of macrophage polarization in obesity-induced inﬂammation and insulin resistance. Circulating monocytes are recruited into the
liver and adipose tissues where they differentiate into either M1 or M2 macrophages. Obesity and a HFD (as well as carbohydrate overload) cause a vicious circle of insulin
resistance and increased free fatty acids, with resultant hepatocyte mitochondrial dysfunction and M1 macrophage polarization in the liver and adipose tissues. These
obesity-related Arg1 lowiNOS highCD11c + adipose tissue macrophages are characterized by enhanced expression of inﬂammatory cytokines, chemokines and mediators
such as TNFa, IL-6, IL-8, CCL2, IL-1b, and iNOS [12], all factors that suppress insulin signaling and de-repress downstream gluconeogenesis via activation of glucose-6-
phosphatase (G6PC) and phosphoenolpyruvate carboxykinase 1 (PCK1). This proinﬂammatory M1 polarization is usually controlled by adiponectin, AMPK, PPARc, and
PPARd, all regulators of energy homeostasis and inducers of regulated fatty acid oxidation and metabolism, skewing macrophage polarization toward the anti-inﬂammatory
M2 phenotype. ACC, acyl-CoA carboxylase; FA, fatty acid.
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demonstrating enhanced systemic inﬂammation, insulin resis-
tance and M1 macrophage inﬁltration in liver and adipose tis-
sues. Since there was no difference in T-cell inﬁltration
between bone marrow chimeras and wild type mice, these data
suggest that the observed liver and adipose tissue inﬂammation
and insulin resistance were caused by macrophages turned
towards M1 polarization by their deﬁciency in AMPK trimers
containing the b1 chain. Moreover, treatment with A769662, a
speciﬁc activator of AMPK b1, shut off fatty acid synthesis via
phosphorylation and inactivation of ACC, enhanced fatty acid oxi-
dation and decreased activation of inﬂammation inducing Jun-N-
terminal kinase (JNK) in wild type but not in AMPK b1 deﬁcient
BMDM. No agonistic effect was found when A769662 treatment
was combined with the mitochondrial pathway inhibitors etom-
oxir or rotenone, conﬁrming that AMPK b1 regulates fatty acid
oxidation via the mitochondrial pathway (Fig. 1).
Notably, constitutive genetic deletion of components of the
AMPK-heterotrimer can either promote [3] or prevent [7] devel-
opment of insulin resistance and the metabolic syndrome under
metabolic stress. With global deletion of AMPKb1, mice lose appe-
tite and body mass due to a decrease of AMPK activity in the
hypothalamus. Thus, even with the associated reduction of hepa-620 Journal of Hepatology 201tic fatty acid oxidation in vivo and in hepatocytes in vitro, these
mutant mice fed a HFD did not develop hepatic steatosis and
insulin resistance [7]. However, globally b2-deﬁcient mice fed a
HFD gained more weight and peripheral as well as central fat
mass, and developed higher insulin resistance compared to their
wild type littermates [3]. The data with the global AMPKb2
knockout (mainly affecting muscle and cardiac tissue) share sim-
ilarities with those of the chimeric mice with AMPKb1 deﬁcient
BMDM, since both displayed higher insulin resistance in adipose
tissue and liver, as measured by the hyperinsulinemic-euglyce-
mic clamp assay. Therefore, AMPK variants in different tissues
and especially different cells fulﬁll divergent tasks in energy
homeostasis and fatty acid metabolism. Speciﬁcally, in fat-laden
macrophages, AMPKb1 appears to mitigate fatty acid-induced
inﬂammation and subsequent insulin resistance.
These results are in line with a recent study demonstrating
that AMPKa1 deﬁcient mice fed a HFD also gained more weight
and showed systemic insulin resistance [8]. Moreover, irradiated
WT mice transplanted with AMPKa1 deﬁcient BMDM developed
insulin resistance but no obesity. However, in their BM trans-
plantation models both studies did not address the possible
contribution of (immune) cells other than monocytes and
macrophages.3 vol. 58 j 619–621
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The novelty of the study by Galic et al. [1] is the connection of
macrophage AMPK activity (as represented by the b1 chain con-
taining complex) with obesity, insulin resistance and NAFLD/
NASH. Another central metabolic regulator, PPARc, has already
been shown to promote peripheral adipogenesis and prominently
repress inﬂammatory genes in macrophages, since its deletion in
macrophages alone drives inﬂammation and insulin resistance in
the liver and peripheral adipose tissue in mice on a normal diet,
generating an even more severe inﬂammatory phenotype than
the AMPK b1 deﬁcient BM chimera [9]. A possible explanation
is that PPARc locates further upstream of AMPK and regulates
its activity through adiponectin [6].
An important issue addressed in this paper is the M1–M2
polarization of macrophages regulated through AMPK. Corre-
spondingly, upon stimulation of macrophages with lipopolysac-
charide (LPS), deletion of AMPKa1 induced expression of the
macrophage TNFa and IL-6, cytokines that are characteristic of
M1 polarization and central to fatty tissue inﬂammation and
NASH [10]. Moreover, a speciﬁc activator of AMPK inhibits LPS-
induced TNFa expression in murine macrophages [11]. On the
other hand, macrophage AMPK expression and activity are sup-
pressed by LPS, which is an important contributor to NAFLD/
NASH.
One recent report mentioned that even the lipid content of
food modulates macrophage polarization [12]. Thus, more M2
macrophages are found in adipose tissues of lean mice fed a nor-
mal vs. high-fat diet. These M2 macrophages in adipose tissues
are protective due to secretion of anti-inﬂammatory cytokines
such as IL-10 [12]. However, there is a yet ill explored connection
between M2 polarization with a ﬁbrogenic cytokine milieu linked
to Th2 T-cell activation [13]. Therefore, induction of M2 macro-
phage polarization to combat fatty tissue inﬂammation and obes-
ity-induced insulin resistance needs to take into account
potential adverse effects on ﬁbrosis progression. This leaves us
with intriguing options, but also novel challenges when develop-
ing macrophage-based therapies of T2D and NAFLD/NASH.Conﬂict of interest
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